ABATE

AC Immune Reports Full Year 2023 Financial Results and Provides a Corporate Update

Retrieved on: 
Thursday, March 14, 2024
University of Geneva, Diagnosis, Target, Down syndrome, MSA, Disease, ALS, PD, Safety, Multiple system atrophy, Patient, PET, Research, Geneva University Hospitals, Amyloid beta, MJFF, ABATE, Smith, University, KOL, Doctor of Philosophy, MD, TAR, IND, Medicine, AC, University of Luxembourg, Cognition, DS, Johnson & Johnson, Janssen, Sahlgrenska University Hospital, CHF, Injection, DSMB, University of Gothenburg, Food, RETAIN, Janssen Pharmaceuticals, Nature Communications, Pharmaceutical industry

Dr. Andrea Pfeifer, CEO of AC Immune SA, commented: “We made significant progress in 2023 advancing our three innovative active immunotherapy programs in Phase 2 clinical trials in Alzheimer’s and Parkinson’s diseases.

Key Points: 
  • Dr. Andrea Pfeifer, CEO of AC Immune SA, commented: “We made significant progress in 2023 advancing our three innovative active immunotherapy programs in Phase 2 clinical trials in Alzheimer’s and Parkinson’s diseases.
  • Six-month Abeta positron emission tomography (PET) imaging results are expected in Q2 2024, and 12-month Abeta-PET data are expected in H2 2024.
  • Comm., 2023) showed that AC Immune’s wholly-owned a-syn-PET tracer ACI-12589 can detect a-syn pathology in multiple system atrophy (MSA) and differentiate MSA from other a-synucleinopathies.
  • PI-2620 was discovered and developed using the Morphomer® platform as part of a research collaboration between AC Immune and Life Molecular Imaging.

Rider Justice Sponsors Accident Scene Management Classes Throughout Spring 2024

Retrieved on: 
Wednesday, January 24, 2024
ABATE, Transport, Curriculum, Insurance, Friends, Lunch, Crash, Rider, Motorcycling, Online shopping

Denver, Colorado--(Newsfile Corp. - January 24, 2024) - Rider Justice , Colorado's top motorcycle law firm, is making it easier and more affordable for motorcycle riders to take accident scene management classes this spring.

Key Points: 
  • Denver, Colorado--(Newsfile Corp. - January 24, 2024) - Rider Justice , Colorado's top motorcycle law firm, is making it easier and more affordable for motorcycle riders to take accident scene management classes this spring.
  • Bikers learning how to safely assist an injured motorcycle rider at a crash scene.
  • Course taught by Accident Scene Management, Inc., and sponsored by Rider Justice.
  • Follow the Rider Justice Events Page: https://riderjustice.com/motorcycle-events/ )
    April 13, 2024: Basic class at Fay Myers Motorcycle World, 9700 E. Arapahoe Rd., Greenwood Village, 80112 (Registration page coming.

AC Immune Progress Update on Phase 2 Active Immunotherapy Clinical Pipeline for Alzheimer's and Parkinson diseases

Retrieved on: 
Wednesday, January 3, 2024
DSMB, AC, Immune system, Vaccine, ABATE, PET, Infection, CHF, PD, Amyloid beta, Pathology, Safety, Patient, Acceleration, Therapy, Tau

Dr. Andrea Pfeifer, CEO of AC Immune SA, commented: “AC Immune has continued steady clinical development progress throughout 2023, and we end the year in a very strong position.

Key Points: 
  • Dr. Andrea Pfeifer, CEO of AC Immune SA, commented: “AC Immune has continued steady clinical development progress throughout 2023, and we end the year in a very strong position.
  • We now have three active immunotherapies from our precision medicine pipeline in Phase 2 clinical testing, with key milestones for ACI-24.060 in 2024.
  • We are moving ever closer to delivering therapeutics that use the immune system to slow the onset and ultimately prevent neurodegenerative diseases, much like vaccines for infectious disease.
  • As recently announced, AC Immune’s development partner launched ReTain, a Phase 2b clinical study to evaluate ACI-35.030 (JNJ-64042056) in patients with preclinical AD.

AC Immune Reports Third Quarter 2023 Financial Results and Provides a Corporate Update

Retrieved on: 
Friday, November 3, 2023
Amyloid, Financial statement, Luxembourg Centre for Systems Biomedicine, PD, Tax, Target, G&A, AC, Conference, Quarter, PET, University of Luxembourg, AAIC, ALS, KOL, Tau, University, The Michael J. Fox Foundation, Safety, ABATE, Diagnosis, D, CHF, Pharmaceutical industry, Medical imaging

Dr. Andrea Pfeifer, CEO of AC Immune SA, commented: “As we look to year-end and into 2024, AC Immune is poised to achieve multiple milestones across our clinical programs.

Key Points: 
  • Dr. Andrea Pfeifer, CEO of AC Immune SA, commented: “As we look to year-end and into 2024, AC Immune is poised to achieve multiple milestones across our clinical programs.
  • We remain on track to report safety and immunogenicity data from the AD cohort of our ABATE trial of ACI-24.060 this year.
  • Then, in the first half of 2024 results are anticipated from the important Abeta-PET imaging analyses on amyloid plaque reduction following 6 months of treatment.
  • The Company’s cash balance provides sufficient capital resources to progress into Q4 2024 without considering receipt of potential future milestone payments.

AC Immune to Host KOL Webinar on Amyloid Plaque PET Imaging in Alzheimer’s Disease as a Surrogate of Clinical Efficacy on November 9, 2023

Retrieved on: 
Thursday, November 2, 2023
Plaque, Host, AC, PET, KOL, University of Pittsburgh, University, ABATE, Patient, Medical imaging, MD

AC Immune to Host KOL Webinar on Amyloid Plaque PET Imaging in Alzheimer’s Disease as a Surrogate of Clinical Efficacy on November 9, 2023

Key Points: 
  • AC Immune to Host KOL Webinar on Amyloid Plaque PET Imaging in Alzheimer’s Disease as a Surrogate of Clinical Efficacy on November 9, 2023
    Lausanne, Switzerland, November 02, 2023 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that it will host a KOL webinar on amyloid plaque PET imaging in Alzheimer’s Disease as a surrogate of clinical efficacy on Thursday, November 9, 2023 at 10:00am ET / 4:00pm CET.
  • The event will feature Prof. Victor Villemagne, MD (University of Pittsburgh), who will discuss the heightened interest in amyloid plaque PET imaging and the methodology, mechanisms, and clinical implications of plaque lowering in light of recent successful trials.
  • The AC Immune team will also highlight its anti-Abeta active immunotherapy candidate, ACI-24.060, currently being evaluated in the ongoing Phase 1b/2 ABATE study for the treatment of Alzheimer’s disease.
  • Initial amyloid-PET imaging analyses in Alzheimer’s patients to assess amyloid plaque reduction after 6 months of treatment with ACI-24.060 in the ABATE trial are anticipated in the first half of 2024.

Large Clinical Trial by the Centers for Disease Control and Prevention, Harvard Pilgrim Health Care Institute, HCA Healthcare and UCI Health Identifies Best Strategy to Prevent Life-Threatening Health Care-Associated ICU Infections

Retrieved on: 
Tuesday, October 10, 2023
Research, Hospitals, Clinical Trials, Health Insurance, Other Health, Managed Care, Health, Pharmaceutical, Science, Chlorhexidine, JAMA, Multimedia, Hospital, Harvard Medical School, Bloodstream infections, Health care, Division, Mupirocin, Suggestion, Bacteria, University of California, Irvine Medical Center, Master of Science, Risk, Intensive care unit, CDC, Antimalarial medication, University, Infection, American Medical Association, CHG, MRSA, Journal, Povidone-iodine, University of California, Irvine School of Medicine, Staphylococcus aureus, REDUCE, Nose, ICU, Additive effect, HCA Healthcare, Korea Disease Control and Prevention Agency, Skin, ABATE, Patient, Harvard Pilgrim Health Care, Pharmaceutical industry, Nursing, MD, Medicine

This strategy is called “decolonization” because it reduces the amount of bacteria on the body in order to reduce infection risk.

Key Points: 
  • This strategy is called “decolonization” because it reduces the amount of bacteria on the body in order to reduce infection risk.
  • The Mupirocin-Iodophor Swap Out Trial directly compared nasal mupirocin to nasal iodophor in the context of chlorhexidine bathing.
  • “This study further supports CDC guidance on using a strategy that combines nasal decolonization plus CHG bathing in ICU patients.
  • The results resolved the question about whether nasal treatment is necessary in addition to chlorhexidine bathing to prevent these ICU infections.

AC Immune Reports Second Quarter 2023 Financial Results and Provides a Corporate Update

Retrieved on: 
Friday, August 4, 2023
University of Geneva, Tau, University, The Michael J. Fox Foundation, Sahlgrenska University Hospital, Luxembourg Centre for Systems Biomedicine, Myawaddy Mingyi U Sa, ABATE, Tax, PET, Financial statement, AC, Gothenburg, Doctor of Philosophy, DS, Down syndrome, Target, University of Gothenburg, AAIC, MD, Patient, Medicine, Polhemus Memorial Clinic, Diagnosis, Poster, AD, FDA, CHF, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, IND, University of Luxembourg, ALS, Food, Conference, Safety, Geneva University Hospitals, D, Pharmaceutical industry, Medical imaging, Fine chemical, Vaccine, Amyloid beta

Dr. Andrea Pfeifer, CEO of AC Immune SA, commented: “We entered the second half of 2023 with strong momentum.

Key Points: 
  • Dr. Andrea Pfeifer, CEO of AC Immune SA, commented: “We entered the second half of 2023 with strong momentum.
  • The first patient with Parkinson’s disease was dosed in the Phase 2 VacSYn clinical trial evaluating ACI-7104.056, AC Immune’s wholly-owned anti-alpha-synuclein (a-syn) active immunotherapy.
  • The Company’s cash balance provides sufficient capital resources to progress into at least Q3 2024 without considering receipt of potential future milestone payments.
  • G&A Expenditures: G&A decreased by CHF 0.7 million to CHF 3.7 million, mostly due to a decrease in personnel expenses.

AC Immune Showcasing Precision Medicine Programs at AAIC 2023

Retrieved on: 
Monday, July 3, 2023
Therapy, ABATE, Amyloid beta, PET, AC, ID, Down syndrome, AAIC, Patient, Alpha-synuclein, Conference, Medical imaging

Lausanne, Switzerland, July 3, 2023 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced upcoming presentations at the annual Alzheimer’s Association International Conference (AAIC 2023), taking place in Amsterdam, The Netherlands, on July 16-20, 2023.

Key Points: 
  • Lausanne, Switzerland, July 3, 2023 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced upcoming presentations at the annual Alzheimer’s Association International Conference (AAIC 2023), taking place in Amsterdam, The Netherlands, on July 16-20, 2023.
  • The presentations will include a poster detailing the design of the Phase 1b/2 ABATE trial evaluating the ACI-24.060 anti-amyloid-beta (Abeta) active immunotherapy in patients with Alzheimer’s disease and individuals with Down syndrome.
  • In addition, AC Immune scientists have organized a “Perspectives Session” focused on TDP-43 proteinopathy in neurodegenerative diseases.
  • Finally, an oral presentation will be given showing detailed data on ACI-12589, AC Immune’s novel positron emission tomography (PET) tracer targeting alpha-synuclein.

AC Immune Receives FDA Fast Track Designation for Anti-Amyloid-beta Active Immunotherapy, ACI-24.060, to Treat Alzheimer’s Disease

Retrieved on: 
Tuesday, June 27, 2023
Therapy, ABATE, Fast Track, AC, CMO, Antibody, DS, Fast track (FDA), Investigational New Drug, Patient, Keck School of Medicine of USC, Neurology, Principal, AD, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, IND, Food, Safety, Disease, Pharmaceutical industry, Vaccine, Amyloid beta

AC Immune Receives FDA Fast Track Designation for Anti-Amyloid-beta Active Immunotherapy, ACI-24.060, to Treat Alzheimer’s Disease

Key Points: 
  • AC Immune Receives FDA Fast Track Designation for Anti-Amyloid-beta Active Immunotherapy, ACI-24.060, to Treat Alzheimer’s Disease
    Lausanne, Switzerland, June 27, 2023 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that it has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for its wholly-owned anti-amyloid beta (Abeta) active immunotherapy (vaccine)-candidate, ACI-24.060, for treatment of Alzheimer’s disease.
  • Furthermore, the first individual with DS has been dosed in ABATE.
  • Dr. Andrea Pfeifer, CEO of AC Immune SA, commented: “We are delighted to see the quality and importance of our ACI-24.060 program reflected in the granting of Fast Track designation, which offers opportunities for expedited development and regulatory review.
  • This regulatory progress underscores the attraction of an active immunotherapy targeting toxic species of Abeta.

AC Immune Holds Annual General Meeting of Shareholders

Retrieved on: 
Friday, June 23, 2023
Chairperson, ABATE, The Michael J. Fox Foundation, Annual, Personalized medicine, Down syndrome, Alpha-synuclein, Advance, ALS, Independent, Annual general meeting, Pharmaceutical industry, Vaccine

Lausanne, Switzerland, June 23, 2023 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that the Company held its Annual General Meeting per Swiss law.

Key Points: 
  • Lausanne, Switzerland, June 23, 2023 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that the Company held its Annual General Meeting per Swiss law.
  • Shareholders cast their votes in person at the Annual General Meeting or through the Independent Proxy appointed by the shareholders.
  • Shareholders re-elected Douglas Williams, Monika Bütler, Carl June, Werner Lanthaler, Andrea Pfeifer, Monica Shaw and Roy Twyman to their positions on the Board of Directors.
  • During the Annual General Meeting, shareholders also approved all other resolutions as proposed by the Board of Directors.